EDEN PRAIRIE, Minn., April 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces an appearance by Chief Executive Officer Dave Rosa on Bloomberg Television's Bloomberg Technology. A replay of the segment, which aired live yesterday, can be viewed at NeuroOne-Bloomberg.
In conversation with host Caroline Hyde, Mr. Rosa discussed the Company’s announcement yesterday about the first implant of its OneRF™ Ablation electrode in a surgery conducted by doctors at a top ranked hospital in the U.S. The limited commercial launch of the OneRF™ Ablation System was announced at the end of March.
Referring to the first implant, Mr. Rosa views the milestone as a tremendous accomplishment for both the Company and the entire field of neurological surgical care. Unique to any solution on the market, NeuroOne’s technology developed a single device that can perform both diagnostic and therapeutic functions utilizing the same electrode. Mr. Rosa sees potential for NeuroOne’s thin film electrode technology, including the OneRF™ Ablation System to support new gene therapies and drug delivery for various Neurological conditions like Alzheimer’s disease, movement disorders and epilepsy, while also being able to directly monitor regions of the brain.
Bloomberg Technology, hosted by Ed Ludlow from San Francisco and Caroline Hyde in New York, is the only daily news program focused exclusively on technology, innovation, and the future of business.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the timing and occurrence of the ablation procedure, the ability of NeuroOne’s thin film electrode technology, including the OneRF™ Ablation System to support new gene therapies and drug delivery for various Neurological conditions like Alzheimer’s disease, movement disorders and epilepsy, while also being able to directly monitor regions of the brain, , and future operations. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
“Caution: Federal law restricts this device to sale by or on the order of a physician”
Contact:
800-631-4030
ir@nmtc1.com
